导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.67% | 1477/4773 |
| 近一周 | -1.18% | 2236/5467 |
| 近一月 | -11.74% | 5106/5421 |
| 近一季 | -20.64% | 4857/5238 |
| 近半年 | 1.26% | 1339/4931 |
| 近一年 | 5.60% | 1498/4400 |
| 近两年 | 119.09% | 427/2954 |
| 近三年 | 70.06% | 339/2253 |
| 成立以来 | 79.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.60% 1875/4961 |
37.02% 860/5312 |
- - |
- - |
| 2025 | 51.40% 438/4813 |
-1.68% 2739/3635 |
3.30% 1060/4076 |
50.59% 299/4524 |
-1.01% 2778/4813 |
| 2024 | 14.70% 1022/3463 |
-3.86% 1571/2808 |
-6.45% 1955/3014 |
29.47% 158/3129 |
-1.49% 1725/3463 |
| 2023 | -18.81% 1828/2656 |
2.30% 1380/2280 |
-7.16% 1796/2385 |
-9.43% 1824/2515 |
-5.60% 1414/2655 |
| 2022 | -29.10% 1587/2207 |
-19.95% 1511/1919 |
5.98% 796/2016 |
-18.48% 1715/2113 |
2.52% 911/2208 |
| 2021 | 12.86% 371/1822 |
-6.91% 1046/1255 |
26.69% 67/1330 |
-6.55% 954/1466 |
2.40% 603/1822 |
| 2020 | 66.56% 88/1250 |
4.00% 95/1028 |
30.74% 48/1067 |
6.02% 880/1164 |
15.54% 201/1184 |
| 2019 | 44.11% 179/1092 |
35.33% 96/754 |
-10.42% 736/804 |
7.68% 81/850 |
10.40% 138/918 |
| 2018 | -29.11% 446/834 |
- - |
- - |
- - |
-11.39% 290/691 |
| 2017 | -7.81% 523/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方创业板ETF VS. 长安沪深300非周期A(740101) |